The

 

Word

 

Is

Getting

 

Out

 

In the News

 
 

PolarityTE™ Announces Application of SkinTE™ on First Patients

SALT LAKE CITY, Dec. 15, 2017 (GLOBE NEWSWIRE) — PolarityTE, Inc. (NASDAQ:COOL) announced that human use of SkinTE™ is underway,READ MORE…

Puma Biotechnology Added to NASDAQ Biotechnology Index

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology IndexREAD MORE…

Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the European Medicines Agency (EMA) has requested thatREAD MORE…

Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer

TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI)READ MORE…

Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting

BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) “Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Sutro Marks Two Drug Development Milestones

SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completedREAD MORE…

Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claimsREAD MORE…

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinicalREAD MORE…

Riot Blockchain’s Coinsquare Receives Milestone Investment

CASTLE ROCK, Colo., Dec. 4, 2017 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that one ofREAD MORE…

Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017

CAMBRIDGE, Mass., Nov. 30, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

Arbutus Announces Presentations at HepDART 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

Riot Blockchain Announces Strategic Investment in Verady, a Blockchain Technology Company

CASTLE ROCK, Colo., Nov. 16, 2017 /PRNewswire/ — Riot Blockchain, Inc., (Nasdaq: RIOT) (the “Company”) today announced it has madeREAD MORE…

Russo Partners Teams with Medovex to Highlight Medical Technology Innovation with DenerveX System for Treatment of Chronic Back Pain

NFL Broadcaster, Agency’s Sports-Health Alliance Leader Solomon Wilcots Kicks Off Campaign with Surgeon Interviews at International Spine Meetings NEW YORK, Nov.READ MORE…

Sigilon Therapeutics to Present at the 2017 Biotech and Money Inv€$tival Showcase Conference in London

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

Puma Biotechnology to Present at Stifel Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Novavax to Present at the Stifel 2017 Healthcare Conference

GAITHERSBURG, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference.READ MORE…

Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements

NORWOOD, MA — (Marketwired) — 11/08/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Novavax Reports Third Quarter 2017 Financial Results

GAITHERSBURG, Md., Nov. 07, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarter and nine monthsREAD MORE…

Curis Reports Third Quarter 2017 Financial Results

LEXINGTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Vericel Reports Third-Quarter 2017 Financial Results

CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) —  Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies forREAD MORE…

Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory andREAD MORE…

Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

LEXINGTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has entered into a loan agreement with Silicon Valley Bank,READ MORE…

Riot Blockchain Enters Agreement for Acquisition of 1,200 Bitcoin Mining Machines Manufactured by Bitmain

CASTLE ROCK, Colo., Nov. 2, 2017 /PRNewswire/ — Riot Blockchain Inc. (Nasdaq: RIOT) (the “Company”) today announced it has enteredREAD MORE…

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

SAN​ ​FRANCISCO,​ ​Nov.​ ​1,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced results from theREAD MORE…

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017

LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Sigilon Therapeutics Appoints Eric Shaff to Board of Directors

CAMBRIDGE, Mass., Nov. 1, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

Sucampo Reports Third Quarter 2017 Financial Results

ROCKVILLE, Md., Nov. 01, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidatedREAD MORE…

Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017

GAITHERSBURG, Md., Oct. 31, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results followingREAD MORE…

Oncobiologics Announces Closing Of Strategic Partnership Deal With GMS Tenshi Holdings

CRANBURY, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), today announced that it closed the sale of the remaining securities to GMS TenshiREAD MORE…

Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., Oct. 31, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies forREAD MORE…

Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases

NORWOOD, MA — (Marketwired) — 10/31/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Aethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017

SAN DIEGO, Oct. 30, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needsREAD MORE…

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m.READ MORE…

Medovex Corporation Comments on President Trump Declaring the Opioid Crisis a National Public Health Emergency

ATLANTA, GA — (Marketwired) — 10/27/17 — Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX®READ MORE…

Corbus Pharmaceuticals Holdings, Inc. Prices Underwritten Public Offering of Common Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory andREAD MORE…

Arbutus Presents HBV Data at 2017 AASLD Liver Meeting

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

Symic​ ​Bio​ ​to​ ​Present​ ​at​ ​Upcoming​ ​Conferences​ ​in​ ​Tokyo​ ​and​ ​Berlin

SAN​ ​FRANCISCO,​ ​Oct.​ ​23,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that the companyREAD MORE…

Riot Blockchain Appoints Eric So to Board of Directors

CASTLE ROCK, Colo., Oct. 23, 2017 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has appointedREAD MORE…

PolarityTE™ Lead Product, SkinTE™, is Approved for Use by Multiple Medical Institutions

SALT LAKE CITY, Oct. 19, 2017 (GLOBE NEWSWIRE) — PolarityTE, Inc. (NASDAQ:COOL) today announced that multiple value analysis committees haveREAD MORE…

Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis

NORWOOD, MA — (Marketwired) — 10/19/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Riot Blockchain Announces Stock Ticker Symbol Change to RIOT

CASTLE ROCK, Colo., Oct. 19, 2017 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) today announced that its NASDAQ Capital MarketREAD MORE…

Medovex Corporation to Participate in World’s Largest Spine Exhibition, NASS 2017

ATLANTA, GA — (Marketwired) — 10/18/17 — Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX®READ MORE…

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virusREAD MORE…

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA — (Marketwired) — 10/17/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Riot Blockchain to Acquire Majority Interest in TESS, a Blockchain Development Company

CASTLE ROCK, Colo., Oct. 17, 2017 /PRNewswire/ — Riot Blockchain Inc. (Nasdaq: BIOP) (the “Company”) today announced it has entered into a definitiveREAD MORE…

Sigilon Therapeutics Introduces Scientific Advisory Board for Guiding Development of Afibromer™ Living Therapeutics

CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences

VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 16, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeuticREAD MORE…

Novavax Announces Leadership Change

GAITHERSBURG, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation asREAD MORE…

Sutro Marks Two Drug Development Milestones

SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completedREAD MORE…

ProMIS™ Neurosciences Provides Third Quarter Update for 2017

TORONTO, Ontario and CAMBRIDGE, Massachusetts – October 11, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery andREAD MORE…

Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC

Zug, Switzerland, October 11, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

PolarityTE™ Names International Leader in Plastic and Reconstructive Surgery Dr. Maurice Nahabedian as Chief Surgical Officer

SALT LAKE CITY, Oct. 06, 2017 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) today announced the appointment of Maurice Nahabedian, MD,READ MORE…

Arbutus to Present HBV Data at 2017 AASLD Liver Meeting

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 03, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

PolarityTE™ Announces FDA Registration of Lead Product – SkinTE™

SALT LAKE CITY, Oct. 03, 2017 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) today announced that the Company’s lead product, SkinTE™,READ MORE…

Symic​ ​Bio​ ​to​ ​Present​ ​at​ ​Upcoming​ ​October​ ​Conferences

SAN​ ​FRANCISCO,​ ​Oct.​ ​2,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Rinko Ghosh,READ MORE…

Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation

ROCKVILLE, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Sigilon Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Sept. 29, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 28, 2017– ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery andREAD MORE…

Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference

ROCKVILLE, Md., Sept. 27, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Auris Medical Announces Transfer to Nasdaq Capital Market

Zug, Switzerland, September 28, 2017 – Auris Medical Holding AG (the “Company”, NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmetREAD MORE…

Auris Medical Provides Board of Directors Update

Zug, Switzerland, September 26, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announcedREAD MORE…

Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis BREAD MORE…

Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference

NORWOOD, MA — (Marketwired) — 09/25/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus

Zug, Switzerland, September 22, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel

ROCKVILLE, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced theREAD MORE…

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

PolarityTE™ Announces Closing of $17.75 Million Above Market Private Placement

SALT LAKE CITY, Sept. 21, 2017 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) today announced the closing of $17.75 million ofREAD MORE…

ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare

TORONTO, ONTARIO and CAMBRIDGE, MA – September 21, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery andREAD MORE…

Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel

ROCKVILLE, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced theREAD MORE…

Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27

ZUG, Switzerland, Sept. 20, 2017 — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

NORWOOD, MA — (Marketwired) — 09/20/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference

ROCKVILLE, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 HealthcareREAD MORE…

ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease

TORONTO, Ontario and Cambridge, Massachusetts – September 19, 2017 – ProMIS Neurosciences, Inc., a company focused on discovery and development ofREAD MORE…

Novavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2READ MORE…

Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Medovex Corporation Initiates Forward Integration-Direct Sales Operations Strategy on Heels of Initial Strong Sales Opportunity in Key German Market

ATLANTA, GA — (Marketwired) — 09/14/17 — Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX®READ MORE…

Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

NORWOOD, MA — (Marketwired) — 09/14/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Curis Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of anREAD MORE…

PolarityTE™ Announces $15.2 Million Above Market Private Placement for Strategic Scale-Up of Commercial Product and Development of the Polarity Platform Pipeline

SALT LAKE CITY, Sept. 14, 2017 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) today announced that it has entered into securitiesREAD MORE…

Symic​ ​Bio​ ​to​ ​Present​ ​at​ ​the​ ​Ladenburg​ ​Thalmann​ ​2017​ ​Annual​ ​Healthcare Conference

SAN​ ​FRANCISCO,​ ​Sept.​ ​18,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Ken Horne,READ MORE…

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

TORONTO, Ontario and Cambridge, Massachusetts – Sept. 13, 2017 – ProMIS Neurosciences, Inc., a company focused on discovery and development ofREAD MORE…

Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Oncobiologics Announces Strategic Partnership With GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS TenshiREAD MORE…

Sigilon Therapeutics to Present at Upcoming September Conferences

CAMBRIDGE, Mass., Sept. 7, 2017 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announcedREAD MORE…

Arbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 07, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, announcedREAD MORE…

Curis to Present at the Baird 2017 Global Healthcare Conference

LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Aethlon Medical to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs inREAD MORE…

Novavax to Participate in the Citi 12th Annual Biotech Conference

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi’s 12th Annual Biotech Conference. READ MORE…

AmpliPhi Biosciences to Present at Rodman & Renshaw 19th Annual Global Investment Conference

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistantREAD MORE…

Puma Biotechnology, Inc. Updated five-year ExteNet analysis in line with prior presentation

First impression ESMO abstracts: iDFS benefit of Nerlynx maintained in updated five-year analysis of ExteNet. The abstract for the upcomingREAD MORE…

Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD

NORWOOD, MA — (Marketwired) — 08/31/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 30, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

DALCOR ACHIEVES 50 PERCENT ENROLLMENT MILESTONE FOR PHASE 3 CARDIOVASCULAR TRIAL

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3READ MORE…

Auris Medical Announces Receipt of Nasdaq Notice

Zug, Switzerland, August 24, 2017 – Auris Medical Holding AG (“the Company”, NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmetREAD MORE…

Symic​ ​Bio​ ​Enrolls​ ​First​ ​Patient​ ​in​ ​MODIFY2​ ​Phase​ ​2​ ​Trial​ ​of​ ​SB-061​ ​for​ ​the Treatment​ ​of​ ​Osteoarthritis

SAN​ ​FRANCISCO,​ ​Aug.​ ​23,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment ofREAD MORE…

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on fourREAD MORE…

Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results

Zug, Switzerland, August 10, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Puma Biotechnology Reports Second Quarter 2017 Financial Results

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30,READ MORE…

Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., Aug. 09, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a clinical-stageREAD MORE…

PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

SOUTH PLAINFIELD, N.J., Aug. 8, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for theREAD MORE…

Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory andREAD MORE…

Novavax Reports Second Quarter 2017 Financial Results

GAITHERSBURG, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended JuneREAD MORE…

AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update Conference Call on August 14

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-basedREAD MORE…

Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke

CLEVELAND, Aug. 07, 2017 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) today announced that the design of its Phase 3 clinical study treating ischemic strokeREAD MORE…

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

NORWOOD, MA — (Marketwired) — 08/07/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

BERKELEY HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

Curis Reports Second Quarter 2017 Financial Results

LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientificREAD MORE…

Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017

Zug, Switzerland, August 3, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Sucampo Reports Second Quarter 2017 Financial Results

ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidatedREAD MORE…

Novavax to Host Conference Call to Discuss Second Quarter 2017 Financial Results on August 8, 2017

Gaithersburg, MD, August 1, 2017 — Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operatingREAD MORE…

Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that NERLYNX™ (neratinib) tablets, formerly known as PB272, is now commercially available by prescriptionREAD MORE…

Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017

LEXINGTON, Mass., July 26, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017

CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (VCEL), a leading developer of autologous expanded cell therapies forREAD MORE…

Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs

GAITHERSBURG, Md., July 24, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced positive topline data from its Phase 2 safety and immunogenicity trialREAD MORE…

Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective

ATHLONE, Ireland, July 24, 2017 (GLOBE NEWSWIRE) — Innocoll Holdings plc (“Innocoll” or the “Company“) and Gurnet Point L.P. (acting through its general partner, Waypoint International GP LLC)READ MORE…

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceuticalREAD MORE…

Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24,READ MORE…

Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing

ATHLONE, Ireland, July 21, 2017 (GLOBE NEWSWIRE) — Innocoll Holdings plc (“Innocoll” or the “Company“) today announces that the High Court of Ireland has approved the acquisitionREAD MORE…

Auris Medical Completes Acquisition of AM-125 Assets

UG, Switzerland, July 20, 2017 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important,READ MORE…

Sucampo Announces Second Quarter 2017 Earnings Call

ROCKVILLE, Md., July 19, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Clarus Closes $910 Million Fund

AMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., July 18, 2017 /PRNewswire/ — Clarus, a leading life science investment firm, announced today that itREAD MORE…

Invenra Enters Collaboration Agreement with Merck to Identify Therapeutic Antibodies Against Challenging Target

MADISON, WI – July 18, 2017 – Invenra today announced a collaboration with Merck, known as MSD outside the UnitedREAD MORE…

Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering

BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceuticalREAD MORE…

U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) today announced that the U.S. Food and Drug Administration (FDA) has approved NERLYNX™READ MORE…

Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ — Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017,READ MORE…

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts

SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro Biopharma’s antibody drug conjugate targeting the CD74 cell surface protein inREAD MORE…

Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting

CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies forREAD MORE…

Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALAREAD MORE…

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

PolarityTE(TM) Expands Clinical Board of Advisors with Focus on World-Renowned Burn and Wound Care Specialists

SALT LAKE CITY, UT — (Marketwired) — 06/30/17 — PolarityTE™, Inc. (NASDAQ: COOL) today announced the appointment of some ofREAD MORE…

Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness

Zug, Switzerland, July 5, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, announced today the appointment of Glenn Prestwich, Ph.D., as ExecutiveREAD MORE…

ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017

TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 5, 2017– ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery andREAD MORE…

PolarityTE(TM) Appoints Distinguished Major General Jay Hood of the U.S. Army as Director of Newly Created Military and Mass Casualty Advisory Board

SALT LAKE CITY, UT — (Marketwired) — 06/27/17 — PolarityTE™, Inc. (NASDAQ: COOL) today announced the appointment of Major GeneralREAD MORE…

Corbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index

NORWOOD, MA — (Marketwired) — 06/26/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development companyREAD MORE…

Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris

Zug, Switzerland, June 22, 2017 — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

PolarityTE(TM) Appoints Clinical Expert and Industry Insider Dr. Wayne Saunders to the Clinical Board of Advisors

SALT LAKE CITY, UT — (Marketwired) — 06/21/17 — PolarityTE™, Inc. (NASDAQ: COOL) today announced the appointment of Wayne J.READ MORE…

SEM Scanner Detects Bedsores Before Visual Diagnosis, Pivotal Study Finds

LOS ANGELES and MANCHESTER, UK, June 20, 2017 – A wireless handheld scanner detected bedsores developing under  the skin earlierREAD MORE…

olero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting

SALT LAKE CITY, June 15, 2017 /PRNewswire/ — Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases,READ MORE…

Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting

NORWOOD, MA — (Marketwired) — 06/15/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Aethlon Medical To Present Clinical Study Results at The BIO International Convention

SAN DIEGO, June 14, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs inREAD MORE…

Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270

ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City

Zug, Switzerland, May 31, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

PolarityTE(TM) Regenerates Full-Thickness Hair-Bearing Skin in Burns and Wounds Using Their Revolutionary Platform Technology

SALT LAKE CITY, UT — (Marketwired) — 06/08/17 — PolarityTE™, Inc. (NASDAQ: COOL) today announced pre-clinical results demonstrating that theREAD MORE…

Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference

NORWOOD, MA — (Marketwired) — 06/08/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing PhaseREAD MORE…

Corbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference

NORWOOD, MA — (Marketwired) — 06/01/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drugREAD MORE…

Oncobiologics Closes On Final Portion Of $15 Million Senior Secured Note And Warrant Offering

CRANBURY, N.J., June 01, 2017 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Aethlon to Present at the LD Micro Invitational Conference on June 6, 2017

SAN DIEGO, May 24, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needsREAD MORE…

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 24, 2017 – ProMIS Neurosciences, a company focused on discovery and development ofREAD MORE…

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

SAN FRANCISCO, May 18, 2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced topline resultsREAD MORE…

Medical Device Company Motus GI Appoints Shervin Korangy to Board of Directors

NEW HOPE, PA, May 15, 2017 – Motus GI Holdings, Inc. (“Motus” or the “Company”), a medical device company dedicatedREAD MORE…

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J., May 11, 2017 (GLOBE NEWSWIRE) — CyclacelREAD MORE…

Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017

Zug, Switzerland, May 4, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting

TORONTO, Ontario – April 27, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”, TSE ticker PMN.TO), a company focused onREAD MORE…

DALCOR PHARMACEUTICALS TO PRESENT AT BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE 2017

LONDON and MONTREAL, April 27, 2017 – DalCor Pharmaceuticals today announced that senior management will present at the Bloom BurtonREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference

ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Oncobiologics Secures Additional Funding

CRANBURY, N.J., April 17, 2017 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES, Calif., April 17, 2017 – Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S.READ MORE…

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announcedREAD MORE…

Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis

NORWORD, MA — (Marketwired) — 03/30/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

NORWOOD, MA — (Marketwired) — 03/08/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

BERKELEY HEIGHTS, N.J., March 07, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announcedREAD MORE…

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

LONDON and MONTREAL, March 7, 2017 – DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with theREAD MORE…

Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention

BOTHELL, Wash., March 06, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology to Present at Cowen’s Health Care Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Biostage to Host Fiscal Year 2016 Update Conference Call

HOLLISTON, Mass., March 2, 2017 /PRNewswire/ — Biostage, Inc. (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organREAD MORE…

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus

Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801 May Qualify for Priority Review Voucher if FDA-Approved Under Provisions in the 21st Century CuresREAD MORE…

Curis to Present at the Cowen and Company 37th Annual Health Care Conference

Curis to Present at the Cowen and Company 37th Annual Health Care Conference (NASDAQ:CRIS) LEXINGTON, Mass., March 01, 2017 (GLOBEREAD MORE…

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference

TNX-102 SL, a Phase 3 Drug Candidate, Recently Granted Breakthrough Therapy Designation by the US FDA Pivotal Study in Military-RelatedREAD MORE…

Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases

CORAL GABLES, Fla., Feb. 27, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), (Catalyst) a biopharmaceutical company focused on  developing READ MORE…

Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss

Zug, Switzerland, Feb. 24, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

Auris Medical and King’s College London Extend Tinnitus Collaboration

– Selection of lead compound for AM-102 program planned for 2017 ZUG, Switzerland, Feb. 22, 2017 (GLOBE NEWSWIRE) — AurisREAD MORE…

Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients andREAD MORE…

Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017

Updates on clinical development of JBT-101 and presentation of new pre-clinical and MOA data; Live video webcast on March 13thREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results

BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Alder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference

BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Arrowhead Reports Fiscal 2017 First Quarter Results

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended DecemberREAD MORE…

Conatus to Present at BIO CEO & Investor Conference

SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide anREAD MORE…

Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo

– Pipeline strengthens with addition of AM-125 as third clinical-stage program – Acquisition of assets related to innovative betahistine productREAD MORE…

Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults

GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinicalREAD MORE…

CFI.co announces Pharnext as winner of the Best Life-Sciences IPO France 2016 Award

London (U.K.), Paris (France), January 17, 2017 – Capital Finance International (CFI), a print journal and online resource reporting onREAD MORE…

Q&A: Starbucks gift cards, leaderboards, and the quest to get patients to take their pills

STATNews Rebecca Robbins January 16, 2017 SAN FRANCISCO — The big truck driving around downtown here last week was plasteredREAD MORE…

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

NORWOOD, MA — (Marketwired) — 01/17/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Healthcare Experts Debut New Technology at JPMorgan Healthcare Conference

SAN FRANCISCO (KGO) — Entrepreneurs and health experts from all over the world flocked to San Francisco for the JPREAD MORE…

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Eutilex to Present at the Biotech Showcase™ 2017 Conference

SEOUL, South Korea, Jan. 6, 2017 /PRNewswire/ — Eutilex Co. Ltd., today announced that the company will present at the 9thREAD MORE…

RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Jan. 6, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and DrugREAD MORE…

Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMITREAD MORE…

Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35thREAD MORE…

Pharnext to Attend January Investor Conferences

Paris, January 4, 2017 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of productsREAD MORE…

Alder BioPharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Passage of the 21st Century Cures Act and its Potential Implications on Biodefense

SAN DIEGO, Dec. 21, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by itsREAD MORE…

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Paris, December 20th , 2016 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio ofREAD MORE…

Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

SAN DIEGO, Dec. 19, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced it has entered into an exclusiveREAD MORE…

Aethlon Announces Initiation of Sepsis-Related Virus Study

SAN DIEGO, Dec. 15, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has initiated a researchREAD MORE…

Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs

SEOUL, South Korea, Dec. 8, 2016 /PRNewswire/ — Eutilex Co. Ltd. today announced that it has completed a $21 billionREAD MORE…

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trialREAD MORE…

Corbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony

NORWOOD, MA — (Marketwired) — 12/05/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia

BERKELEY HEIGHTS, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Novavax to Participate in the Citi 2016 Global Healthcare Conference

GAITHERSBURG, Md., Nov. 30, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the CitiREAD MORE…

Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder

CERC-301 misses primary endpoint but the 20 mg dose shows clinically meaningful efficacy signals at Day 2; Management to HoldREAD MORE…

Clinical Data for BackBeat Medical’s Programmable Hypertension Control Therapy to Be Presented at ICI Meeting 2016

NEW HOPE, Pa., Nov. 29, 2016 /PRNewswire/ — BackBeat Medical Inc., a medical technology company developing novel cardiac stimulation-based therapies forREAD MORE…

Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

NORWOOD, MA — (Marketwired) — 11/29/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine

BOTHELL, Wash., Nov. 28, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Innocoll Holdings plc Announces Third Quarter 2016 Financial and Operating Results and Provides Corporate Update

ATHLONE, Ireland, Nov. 22, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stageREAD MORE…

Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference

CORAL GABLES, Fla., Nov. 21, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

New Jersey Technology Council Honored Chromocell Corporation at the 2016 Awards Celebration

NORTH BRUNSWICK, N.J., Nov. 18, 2016 /PRNewswire/ — New Jersey Technology Council (NJTC) has honored Chromocell Corporation along with the region’sREAD MORE…

Pharnext Announces that the Data Safety Monitoring Board Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Paris, November 17, 2016 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of productsREAD MORE…

Pharmaceutical Companies Lose $637 Billion in Revenue Annually Due to Medication Nonadherence

NORWALK, Conn., Nov. 16, 2016 /PRNewswire/ — HealthPrize Technologies today announced the publication of an update to a research paperREAD MORE…

International Stem Cell Corporation Announces Operating Results for the Three and Nine-months ended September 30, 2016

CARLSBAD, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-basedREAD MORE…

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoproteinREAD MORE…

Oncobiologics Announces Presentation Of Final Data From Phase 1 Clinical Study Of ONS-3010 (HUMIRA® Biosimilar)

CRANBURY, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Innocoll Holdings plc to Present at the Stifel 2016 Healthcare Conference

ATHLONE, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device companyREAD MORE…

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

SAN DIEGO , Nov. 14, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of four postersREAD MORE…

Arrowhead Pharmaceuticals Presents New Data on ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oralREAD MORE…

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 11/14/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Gaumard to Show New Touch-Screen Wireless Simulation Interface at AHA Scientific Sessions

MIAMI, Nov. 11, 2016 /PRNewswire/ — Gaumard® Scientific Company will demonstrate how it is transforming CPR training with value-priced simulators and skillsREAD MORE…

DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

LONDON, Nov. 10, 2016 /PRNewswire/ — DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC,READ MORE…

International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease at the Neuroscience 2016 Conference

CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Auris Medical Provides Business Update and Reports Third Quarter 2016 Financial Results

ZUG, Switzerland, Nov. 10, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeuticsREAD MORE…

Novavax Reports Third Quarter 2016 Financial Results

GAITHERSBURG, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarterREAD MORE…

Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update Company to Host Quarterly Conference Call at 8:30READ MORE…

Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference

LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, itsREAD MORE…

Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide anREAD MORE…

Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates

SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine

TARP ɣ-8 selectivity may lead to enhanced antiseizure therapy BALTIMORE, MD — (Marketwired) — 11/07/16 — Cerecor, Inc. (NASDAQ: CERC),READ MORE…

Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Eutilex Names Agustin de la Calle Chief Business Officer

SEOUL, South Korea, Nov. 7, 2016 /PRNewswire/ — Eutilex Co. Ltd. today announced that it has appointed Agustin de la Calle,READ MORE…

Auris Medical to Announce Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016

Basel, Switzerland, Nov. 03, 2016 (GLOBE NEWSWIRE) — Zug, Switzerland, Nov. 3, 2016 – Auris Medical Holding AG (NASDAQ: EARS),READ MORE…

Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH forREAD MORE…

Curis Reports Third Quarter 2016 Financial Results

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016

GAITHERSBURG, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and AnalystREAD MORE…

Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 10th, 2016

CORAL GABLES, Fla., Nov. 01, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

Alder BioPharmaceuticals to Present at Two Upcoming November Conferences

BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Arrowhead Pharmaceuticals to Present at Upcoming Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25th Annual CreditREAD MORE…

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

BackBeat Medical Clinical Data Presented at TCT 2016 Show Continued Reduction in Blood Pressure Over One Year with Cardiac Pacing-Based Hypertension Treatment

NEW HOPE, Pa., Oct. 31, 2016 /PRNewswire/ — BackBeat Medical Inc. today announced the presentation of data demonstrating a continued significantREAD MORE…

Catalyst Pharmaceuticals Receives Special Protocol Assessment (SPA) from the FDA for Second Phase 3 Clinical Trial Evaluating Firdapse for the Treatment of LEMS

CORAL GABLES, Fla., Oct. 31, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and National Institute on Drug Abuse

SANTA MONICA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacologicalREAD MORE…

Sucampo Announces Third Quarter 2016 Earnings Call

ROCKVILLE, Md., Oct. 28, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Alder BioPharmaceuticals Announces Third Quarter 2016 Financial and Operating Results

BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016

LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Clinical Data for BackBeat Medical’s Programmable Hypertension Control Therapy to Be Presented at TCT 2016

NEW HOPE, Pa., Oct. 26, 2016 /PRNewswire/ — BackBeat Medical Inc. today announced that clinical data for the company’s patented ProgrammableREAD MORE…

Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting(R)

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company’sREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results

BOTHELL, Wash., Oct. 20, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology Prices Public Offering of Common Stock

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000READ MORE…

Clinical Data Demonstrate Effectiveness of MOTUS GI™’s Pure-Vu™ System in Achieving Adequate Bowel Prep in Poorly Prepped Colonoscopy Patients

TIRAT CARMEL, Israel, Oct. 18, 2016 – MOTUS GI, a medical device company dedicated to improving colonoscopy outcomes and experiences,READ MORE…

The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si

PARSIPPANY, N.J.–(BUSINESS WIRE)–The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for allREAD MORE…

Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union

Company on track to complete Phase 2 study in cystic fibrosis in 2016; Phase 2 topline results expected Q1 2017READ MORE…

International Stem Cell Corporation Announces Positive Efficacy Results in Traumatic Brain Injury

CARLSBAD, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study

FREMONT, Calif., Oct. 14, 2016 /PRNewswire/ — Quark Pharmaceuticals, Inc. today announced the launch of www.EyeActNow.com to promote public awareness andREAD MORE…

Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals

TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical companyREAD MORE…

Catalyst Pharmaceuticals to Present at 15th Annual BIO Investor Forum

CORAL GABLES, Fla., Oct. 13, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting

PARSIPPANY, N.J.–(BUSINESS WIRE)–Oct. 13, 2016– The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700READ MORE…

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 10/13/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

NORTH BRUNSWICK, N.J. and TOKYO, Oct. 12, 2016 /PRNewswire/ — Chromocell Corporation and Astellas Pharma Inc. announced today that theREAD MORE…

Symic Bio to Present at the 15​ th​ Annual BIO Investor Forum

SAN FRANCISCO, Oct. 11, 2016 – Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focusedREAD MORE…

Alder BioPharmaceuticals Promotes Larry Benedict to Executive Vice President of Finance and Principal Accounting Officer

BOTHELL, Wash., Oct. 11, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage company developing monoclonal antibody therapeutics, todayREAD MORE…

Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

ZUG, Switzerland, Oct. 11, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developingREAD MORE…

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients

SOUTH PLAINFIELD, N.J., Oct. 6, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new data supporting the potential benefitREAD MORE…

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B

PASADENA, Calif. & HOPKINTON, Mass.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stageREAD MORE…

The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si

PARSIPPANY, N.J.–(BUSINESS WIRE)–Oct. 5, 2016– The Medicines Company (NASDAQ:MDCO) today provided a progress update on the ongoing ORION-1 study ofREAD MORE…

International Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease

CARLSBAD, Calif., Oct. 05, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Pharnext Announces Support of the First Patient-Centered Charcot-MarieTooth Summit Organized by the Hereditary Neuropathy Foundation

Paris, Oct. 4, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension,READ MORE…

ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement

TORONTO, Sept. 28, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH) is pleased to announce today that InstitutionalREAD MORE…

Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

THOUSAND OAKS, Calif. and PASADENA, Calif. (Sept. 29, 2016) — Amgen (NASDAQ: AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) todayREAD MORE…

Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance

BOTHELL, Wash., Sept. 21, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit

NORWOOD, MA–(Marketwired – September 19, 2016) – Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drugREAD MORE…

Pharnext Confirms its Continuous Support of the Hereditary Neuropathy Foundation to Increase Global Awareness of Charcot-Marie-Tooth Disease

Paris, September 15, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress

BOTHELL, Wash., Sept. 15, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Auris Medical Announces AAO-HNSF Annual Meeting Activities

ZUG, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis

NORWOOD, MA — (Marketwired) — 09/12/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness

ZUG, Switzerland, Sept. 9, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developingREAD MORE…

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

SOUTH PLAINFIELD, N.J., Sept. 7, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of theREAD MORE…

Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference

ATHLONE, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device companyREAD MORE…

Novavax to Host 4th Annual Investor and Analyst Meeting

GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual InvestorREAD MORE…

Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference

CORAL GABLES, Fla., Sept. 08, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developingREAD MORE…

Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer

Addition to Leadership Team Expands Commercialization Focus and Supports Continued Successful Advancement of ALD403 for Migraine Prevention BOTHELL, Wash., Sept.READ MORE…

Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT,READ MORE…

Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma BERKELEY HEIGHTS, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) — CyclacelREAD MORE…

Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

Paris, September 1, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcomingREAD MORE…

Oncobiologics To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences

BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Symic to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference

SAN FRANCISCO, Aug. 29, 2016 – Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules ofREAD MORE…

Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

AUGUST 29, 2016 Company provides timing updates TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), todayREAD MORE…

DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Sites open in Europe and New Zealand Enrollment on schedule in trial of dalcetrapib in genetically distinct patients with acuteREAD MORE…

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib hasREAD MORE…

HealthPrize teams up with Walgreens to get patients to follow prescriptions

Westfair Online   HealthPrize teams up with Walgreens to get patients to follow prescriptions http://westfaironline.com/81301/healthprize-teams-up-with-walgreens-to-get-patients-to-follow-prescriptions/   Bob Rozycki August 16,READ MORE…

Walgreens hopes gamelike program will make taking meds easier

The Chicago Tribune   Walgreens hopes gamelike program will make taking meds easier http://www.chicagotribune.com/business/ct-walgreens-games-drugs-0816-biz-20160815-story.html   Lisa Schencker August 16, 2016READ MORE…

Walgreens to offer Healthprize’s medication adherence tool to select patients online

MobiHealthNews   Walgreens to offer Healthprize’s medication adherence tool to select patients online http://mobihealthnews.com/content/walgreens-offer-healthprizes-medication-adherence-tool-select-patients-online   Heather Mack August 16, 2016READ MORE…

Five things for pharma marketers to know: Tuesday, August 16, 2016

Medical Marketing & Media   Five things for pharma marketers to know: Tuesday, August 16, 2016 http://www.mmm-online.com/roundup/five-things-for-pharma-marketers-to-know-tuesday-august-16-2016/article/516300/   Virginia LauREAD MORE…

Walgreens partners for game-based drug adherence platform

Fierce Biotech   Walgreens partners for game-based drug adherence platform http://www.fiercebiotech.com/medical-devices/walgreens-to-market-healthprize-s-game-based-drug-adherence-platform   Amirah Al Idrus August 16, 2016    READ MORE…

Walgreens wants you to take your pills

Crain’s Business Chicago   Walgreens wants you to take your pills http://www.chicagobusiness.com/article/20160816/NEWS03/160819917/walgreens-launches-gamified-patient-engagement-app-to-boost-drug   Duncan Moore Jr. August 16, 2016  READ MORE…

Walgreens hopes gamelike program will make taking meds easier

Business Walgreens hopes gamelike program will make taking meds easier Walgreens at State and Randolph Streets in Chicago on JulyREAD MORE…

Patient, wife share their story of how brain disorder study changed their lives

ORLANDO, Fla. – A Central Florida doctor is conducting the first-ever clinical trial in Orlando for people with the brainREAD MORE…

Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates

SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Accera Appoints C. Evan Ballantyne as Chief Financial Officer

Accera Appoints C. Evan Ballantyne as Chief Financial Officer BOULDER, Colo., Aug. 2, 2016 – Accera, Inc., a clinical-stage biotechnologyREAD MORE…

Pharnext Announces the Appointment of René Goedkoop as Chief Medical Officer and François Chamoun as General Counsel

Paris, July 26, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results

BOTHELL, Wash., July 19, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation Cardiovascular Genetics

Effects on C-reactive protein and cholesterol efflux support dalcetrapib benefits on cardiovascular outcomes in patients with AA genotype of ADCY9READ MORE…

Sucampo Provides Update on Cobiprostone Development Program

ROCKVILLE, Md., July 11, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced theREAD MORE…

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.D., willREAD MORE…

Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease

TORONTO – June 30, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (CNS) pharmaceuticalREAD MORE…

Symic Appoints Carolyn Bertozzi, Ph.D., to Scientific Advisory Board

SAN FRANCISCO, June 28, 2016 – Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect theREAD MORE…

Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 06/16/16 — RELATED LINKS PDF Release PDF Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” orREAD MORE…

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Alder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology

BOTHELL, Wash., June 06, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults

(GLOBE NEWSWIRE via COMTEX) —  GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine companyREAD MORE…

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting | Puma Biotechnology Investor Center LOS ANGELES–(BUSINESSREAD MORE…

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced thatREAD MORE…

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ Lab

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announcedREAD MORE…

StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study

StemCells, Inc. – Investor Relations – News Release NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ:STEM), aREAD MORE…

Symic to Present at Upcoming May Conferences

Symic to Present at Upcoming May Conferences – Chief Financial Officer Jocelyn Jackson to present at BioEquity Europe 2016 inREAD MORE…

Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A

PARIS, April 25, 2016 – Pharnext today announced the opening of the first U.S. trial site for its PLEO-CMT pivotalREAD MORE…

Curis and Aurigene Present Preclinical Data from Multiple Programs at AACR Annual Meeting

LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016

Public Company Information: NYSE: PBYI US74587V1070 LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drugREAD MORE…

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

SEATTLE, April 19, 2016 — Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the UniversityREAD MORE…

Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors

Preclinical Data Presented at the AACR 2016 Meeting BERKELEY HEIGHTS, N.J., April 18, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc.READ MORE…

Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

New website launched at www.arrowheadpharma.com, ticker symbol remains ARWR PASADENA, Calif., April 6, 2016 — Arrowhead Research Corporation (NASDAQ: ARWR)READ MORE…

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

— Latest analysis of data presented at the American Society of Hematology’s annual meeting in December, 2015 — — CUDC-907READ MORE…

Arrowhead to Present at Upcoming April Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the companyREAD MORE…

Association of Bioscience Financial Officers (ABFO) 2016 National Conference Set for May 24-27 in San Diego

EARLY BIRD REGISTRATION ENDS SOON!  Only 8 more days to take advantage of the Early Bird registration. You can saveREAD MORE…

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results

BERKELEY HEIGHTS, N.J., March 17, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Novavax Appoints Bob Darius Senior Vice President, Quality Operations

GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS(R) Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today reportedREAD MORE…

GEN Roundtable Panel Discusses Technologies and Strategies for Product Development

Seven Companies to Watch | Insight & Intelligence™ | GEN In January, San Francisco was the annual venue for theREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 28th Annual ROTH Conference

ROCKVILLE, Md., March 09, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

BIND Therapeutics to Report Fourth Quarter and Year-End 2015 Financial Results on March 15, 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®,READ MORE…

StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million

StemCells, Inc. – Investor Relations – News Release NEWARK, Calif., March 09, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ:STEM) todayREAD MORE…

Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference

TORONTO, March 7, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developingREAD MORE…

Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, andREAD MORE…

Drug Delivery Roundtable: More than the Pill

One of the more exciting trends in science today is the innovation taking place in the way medicines are administered,READ MORE…

Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from theREAD MORE…

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Financial Results

SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016

LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Immunexpress Presents Results Indicating the Utility of SeptiCyte™ for the Diagnosis of Sepsis in Critically Ill Children at the 45th Annual Society of Critical Care Medicine Congress

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of dataREAD MORE…

Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek®

DUBLIN, Ohio–(BUSINESS WIRE)–Feb. 11, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that the first patient has been enrolled inREAD MORE…

AZD2811 ACCURINS(R) Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

BIND Therapeutics and AstraZeneca Publish Preclinical Data Illustrating ACCURINS® Ability to Utilize Proprietary Hydrophobic Ion Pairing to Increase Biodistribution toREAD MORE…

Immunexpress Announces Presentations at the 45th Annual Society of Critical Care Medicine Congress on the Utility of SeptiCyte® Lab

SEATTLE, Feb. 10, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, todayREAD MORE…

Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis

CORAL GABLES, Fla., Feb. 08, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies forREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 Leerink Global Healthcare Conference

ROCKVILLE, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Alder BioPharmaceuticals to Present at Leerink Partners 5th Annual Global Healthcare Conference

BOTHELL, Wash., Feb. 04, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference

DUBLIN, Ohio–(BUSINESS WIRE)–Feb. 4, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer,READ MORE…

J.P. Morgan Roundtable: Biotech’s Reputation Tarnished By Drug Pricing Concerns 

Scrip Intelligence 25 January 2016  Mandy Jackson Big pharma companies are used to being criticized for high drug prices, butREAD MORE…

StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference

NEWARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make presentations on the Company’sREAD MORE…

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced thatREAD MORE…

J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations

Scrip Intelligence   J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations 24 January 2016  Mandy JacksonREAD MORE…

Novavax to offer $200M in convertible debt; shares down 7% premarket

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023 – GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE)READ MORE…

Smartwatches to gather data on Parkinson’s patients in Toronto biotech company’s clinical trial

A Toronto-based biotech company is teaming up with the Michael J. Fox Foundation, strapping smartwatches on Parkinson’s patients to test theirREAD MORE…

Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development

Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development (NASDAQ:PTCT) SOUTH PLAINFIELD, N.J., Jan. 7, 2016 /PRNewswire/READ MORE…

Biotech tie-up to use smartwatches in Parkinson’s drug trials

By David Crow Financial Times, Health January 7, 2016  Chipmaker Intel and Michael J Fox’s Parkinson’s foundation are teaming upREAD MORE…

Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

SAN DIEGO, Jan. 05, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. today announced that the three-month, double-blind, placebo-controlled stage ofREAD MORE…

BIND Therapeutics to Present at Biotech Showcase 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, todayREAD MORE…

Puma Biotechnology to Present at J.P. Morgan Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned Subsidiary

TORONTO – Cynapsus Therapeutics Inc., a specialty central nervous system  pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use,READ MORE…

Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization

GAITHERSBURG, Md., Dec. 03, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, reported in Scientific Reports ‒ aREAD MORE…

Symic Secures $25 Million in Series A-2 Financing to Advance Clinical-Stage Biotherapeutics Platform

SAN FRANCISCO, Dec. 1, 2015 /PRNewswire/ — Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellularREAD MORE…

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products

CARLSBAD, CA–(Marketwired – December 01, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Puma Biotechnology Provides Update from Meeting with European Medicines Agency

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meeting with the EuropeanREAD MORE…

Gaumard® Scientific to Showcase Trauma HAL, the Battlefield Trauma Patient Simulator, at I/ITSEC 2015

MIAMI, Nov. 30, 2015— Gaumard Scientific Company today announced it will showcase Trauma HAL® and Pedi HAL® at I/ITSEC 2015, set for Nov. 30 – Dec.READ MORE…

Sucampo Announces Webcast of Its Presentation at Piper Jaffray 27th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 25, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP), a global biopharmaceutical company, today announced that itREAD MORE…

CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

BERKELEY HEIGHTS, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announcedREAD MORE…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015

NORWOOD, MA — (Marketwired) — 11/23/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cynapsus Therapeutics Expands Senior Leadership Team

TORONTO, Nov. 19, 2015 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty CNS pharmaceutical company developing and preparingREAD MORE…

PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis

SOUTH PLAINFIELD, N.J., Nov. 19,  2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment ofREAD MORE…

StemCells, Inc. Interim Trial Data Show Motor Improvement in Patients With Cervical Spinal Cord Injury

NEWARK, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-basedREAD MORE…

BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, todayREAD MORE…

Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ — Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at theREAD MORE…

Symic Biomedical Selects Osteoarthritis Clinical Candidate

SAN FRANCISCO, Nov. 17, 2015​– Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellularREAD MORE…

Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late-breaking oralREAD MORE…

Novavax to Make Multiple Presentations at RSV Vaccines for the World

GAITHERSBURG, Md., Nov. 16, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a PhaseREAD MORE…

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of two posters, bothREAD MORE…

Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President’s Press Conference at AASLD Annual Meeting

SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company’s late-breaking oral presentationREAD MORE…

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLDREAD MORE…

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015

CARLSBAD, CA–(Marketwired – November 16, 2015) – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-basedREAD MORE…

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phasesREAD MORE…

Cynapsus Reports Third Quarter 2015 Financial Results and Recent Developments

Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty central nervous system (“CNS”) pharmaceutical company developingREAD MORE…

Clinical Trial Results Disclosure by Large Biopharmaceutical Companies Falls Below Legal and Ethical Standards, Study Published in BMJ Open Shows

Bioethics International, a not-for-profit organization focused on the ethics and governance of how medicines are researched, developed, marketed and madeREAD MORE…

StemCells, Inc. Announces Webcast to Discuss Interim Results From the First Cohort in Its Phase II Study in Cervical Spinal Cord Injury

StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of theREAD MORE…

Arrowhead to Present at Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentationsREAD MORE…

Conatus Pharmaceuticals to Present at Stifel 2015 Healthcare Conference

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook atREAD MORE…

Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, andREAD MORE…

BIND Therapeutics to Present at 2015 Stifel Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that AndrewREAD MORE…

Novavax to Present at the Stifel 2015 Healthcare Conference

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Astellas to Acquire Ocata Therapeutics

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:READ MORE…

Cellular Dynamics Announces Collaboration with Roche

Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with Roche to supply CDI’s induced pluripotent stemREAD MORE…

Puma Biotechnology Reports Third Quarter 2015 Financial Results

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30,READ MORE…

PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD

SOUTH PLAINFIELD, N.J., Nov. 9, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financialREAD MORE…

BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today reported data demonstratingREAD MORE…

Mechanistic Rationale for CYC065, Cyclacel’s CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announced the presentation of preclinical data demonstrating the mechanistic rationaleREAD MORE…

Novavax Reports Third Quarter 2015 Financial Results

Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Innovative and Realistic Gaumard Adult, Pediatric and Neonatal Simulators to be Showcased at the American Heart Association Scientific Sessions 2015

MIAMI, Nov. 6, 2015— Gaumard® Scientific Company today announced that it will provide demonstrations of its innovative HAL patient simulators and Newborn ToryREAD MORE…

Symic Biomedical Appoints Kamal Egodage, Ph.D., MBA, VP of Development & Manufacturing and Grace Wong-Sarad, VP and Controller

SAN FRANCISCO, Nov. 5, 2015​– Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix (ECM),READ MORE…

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief ExecutiveREAD MORE…

Alder BioPharmaceuticals to Present at the Credit Suisse 24th Annual Healthcare Conference

BOTHELL, Wash., November 3, 2015 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics forREAD MORE…

International Stem Cell Corporation Moves Forward With Parkinson’s Disease Clinical Trials in Australia

CARLSBAD, CA–(Marketwired – November 03, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

PTC Therapeutics Announces Launch of STRIVE Grant Award Program for Cystic Fibrosis

SOUTH PLAINFIELD, N.J., Oct. 29, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its StrategiesREAD MORE…

Catalyst Pharmaceuticals Announces Poster Presentation at 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

CORAL GABLES, Fla., Oct. 27, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial

SAN FRANCISCO, Oct. 27, 2015 – Symic Biomedical, a clinical‐stage biotherapeutics platform company developing compounds that target the extracellular matrixREAD MORE…

BIND Therapeutics’ Presentations at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, todayREAD MORE…

Gaumard Patient Simulators to be Featured in Real-World Emergency Medical Training Scenarios at 2015 ACEP Scientific Sessions

MIAMI, Oct. 23, 2015 – Gaumard® Scientific Company today announced that it will demonstrate its innovative patient simulators at theREAD MORE…

Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults

GAITHERSBURG, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

BERKELEY HEIGHTS, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinicalREAD MORE…

Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

SAN DIEGO, Oct. 20, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that a late-breaking abstract detailing resultsREAD MORE…

Novira Therapeutics to Present at 2015 AASLD Meeting in San Francisco

DOYLESTOWN, Pa., Oct. 20, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curativeREAD MORE…